Gilead Sciences, Inc.

Gilead Sciences, Inc. is a US biopharma company. It discovers, develops and markets medicines for viral infections, liver diseases, cancer and inflammatory diseases. Its shares trade on Nasdaq under the ticker GILD.

The company's commercial weight lies in HIV; single-tablet regimens for treatment and drugs aimed at preventing infection form the basis of this portfolio, and an injectable preventive therapy given twice a year has also been added to this area. Medicines for hepatitis B and C and certain chronic liver diseases make up another main area. On the oncology side, there is an antibody-drug conjugate used in tumors such as breast cancer, as well as cell therapies developed through the Kite unit.

For biopharma stocks, patent expiries, drug pricing policies, clinical trial results and the commercial success of new approvals are watched. On the GILD page at Lzzo.com, the share price appears in US dollars and can be converted into Turkish lira, euros or pounds sterling. A price history chart, technical indicators, the source of the data and the time of the last update are also on the page.